Tasigna chemotherapy is popularly used throughout the United States for chronic myeloid leukemia, but recent reports indicate this drug could induce potentially fatal cardiovascular events. While Tasigna chemotherapy is still widely used in the patient population, the medical community is wary of potential cardiac complications like atherosclerosis and other circulation issues.
Tasigna (Ninotinb) was approved by the FDA in 2007 with a black box warning regarding other side effects. Tasigna chemotherapy earned manufacturer Novartis $1.7 billion in 2016. Tasigna chemotherapy works by blocking tyrosine kinase protein Bcr-Abl, which is a protein that can stimulate the growth of cancer cells.
These proteins are made by chronic myeloid leukemia cells that have an unusual feature called the Philadelphia chromosome, making Taisgna chemotherapy the ideal choice for this particular cancer. It is important to note that 95% of patients with myeloid leukemia have the Philadelphia chromosome, so it is likely most of these patients will opt for Tasigna chemotherapy.
Overview of Tasigna Chemotherapy Risks
Numerous studies have indicated this cancer treatment drug may have serious side effects including the clogging and swelling of arteries. Also known as atherosclerosis, this condition occurs when the artery walls thicken and harden while plaque buildups up around them. If allowed to…